According to recent reports, ovarian serous borderline tumor (SBT) harboring theBRAFV600E mutation is associated with a lower risk of progression to low-grade serous carcinoma. Preliminary observations suggest that there may be an association between eosinophilic cells (ECs) and the above-mentioned mutation, so this study aimed to evaluate interobserver reproducibility for assessing ECs. Forty-two samples of SBTs were analyzed for ECs with abundant eosinophilic cytoplasm. Immunohistochemical staining and genetic pro-filing were performed in all cases to verify theBRAFV600E mutation. ABRAFV600E mutation was found in 19 of 42 (45%) cases. Inter-observer reproducibility in the assessment of ECs was substantial (κ = 0.7). The sensitivity and specificity for predicting the mutation were 79% and 91%, respectively. Patients withBRAF-mutated SBTs were significantly younger than those without mutation (p= 0.005). SBTs withBRAFmutation were less likely to be accompanied by non-invasive implants than wild-type SBT: 12% (2/17) versus 33% (6/18). Seven cases were excluded due to incomplete cytoreductive surgery. Nevertheless, Fisher’s exact test showed no significant differences between the two groups (p= 0.228). Overall, this study strengthens the idea that ECs in ovarian SBTs may represent a mutation with prognostic significance, which can serve as a primary screening test forBRAFV600E mutation in this pathologic entity.
近期研究显示，携带BRAFV600E突变的卵巢浆液性交界性肿瘤（SBT）进展为低级别浆液性癌的风险较低。初步观察提示嗜酸性细胞（ECs）可能与上述突变存在关联，因此本研究旨在评估观察者间对ECs判读的一致性。研究人员对42例SBT样本中具有丰富嗜酸性胞质的ECs进行分析，所有病例均通过免疫组化染色及基因谱检测验证BRAFV600E突变状态。结果显示42例中有19例（45%）存在BRAFV600E突变，观察者间对ECs的评估具有高度一致性（κ=0.7）。ECs预测该突变的敏感性和特异性分别为79%和91%。携带BRAF突变的SBT患者年龄显著低于无突变患者（p=0.005）。与野生型SBT相比，BRAF突变型SBT伴非浸润性种植的概率更低（12% [2/17] vs 33% [6/18]），其中7例因肿瘤细胞减灭术不完整被排除，但Fisher精确检验显示两组间无显著差异（p=0.228）。本研究进一步证实卵巢SBT中的ECs可能代表具有预后意义的突变表型，可作为该病理类型中BRAFV600E突变的一线筛查指标。
Eosinophilic Cells in Ovarian Borderline Serous Tumors as a Predictor of BRAF Mutation
肿瘤(癌症)患者之家